(HealthDay News) — For patients with heart failure with reduced ejection fraction and predominantly central sleep apnea, adaptive servo-ventilation does not improve outcome, according to a study ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — In a substudy of CAT-HF, patients with HF, sleep-disordered breathing and an implantable cardiac ...

Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...

MONTREAL — The treatment of central sleep apnea in heart failure patients was in the spotlight here at CHEST 2015, as experts debated whether or not to completely reject the use of adaptive servo ...

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

Using Philips PAP solutions, results resurface conversation around ASV therapy use for complex sleep apnea and its potential to improve quality of life Amsterdam, the Netherlands – Royal Philips (NYSE ...

The results of the first randomized, controlled trial to assess adaptive servo-ventilation (ASV) for central sleep apnoea were expected to confirm the positive findings from previous observational ...

Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.

A new clinical practice guideline developed by a task force of the American Academy of Sleep Medicine provides updated recommendations for the treatment of central sleep apnea. Available online as an ...

ResMed announced primary results from a multicenter, randomized controlled phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF ...

SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...